New study checks if cancer drug olutasidenib changes how other medicines work
NCT ID NCT07486713
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensure safe and effective dosing when olutasidenib is used alongside other medicines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olutasidenib
What this could lead to
If successful, this study could help doctors understand how olutasidenib interacts with other medications, leading to safer treatment plans for patients with IDH1-mutated cancers.
What could go wrong
This is a small, early-phase drug interaction study, not designed to test whether olutasidenib works against cancer. Results may not apply to all patients or predict real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Presbyterian Hospital-Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
-
UCI Irvine Health
RECRUITINGOrange, California, 92868, United States